Actively Recruiting
From Genetics to Transcriptomics to Unravel the Mechanisms Behind a Poor Outcome in Multiple Sclerosis
Led by Nantes University Hospital · Updated on 2026-03-19
130
Participants Needed
1
Research Sites
391 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
MS is a heterogeneous disease either in its response to treatment or clinical manifestation. Indeed, the natural history of MS is varying from a benign condition to a devastating and rapidly incapacitating disease. Clinical heterogeneity could also be cellular and / or molecular. The aim is to identify from OMIC analyses, at the early stage of the disease, differentially expressed molecules and / or cell subpopulations derived from CD8 + T lymphocytes and / or CD4 + T lymphocytes and / or B lymphocytes and monocytes from patients with aggressive versus non-aggressive, compared to a cohort of healthy controls
CONDITIONS
Official Title
From Genetics to Transcriptomics to Unravel the Mechanisms Behind a Poor Outcome in Multiple Sclerosis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged 18 years or older
- Clinical isolated syndrome (CIS) with or without dissemination in space
- Patients affiliated to an appropriate health insurance
- For Aggressive MS group: start of a 2nd line therapy within two years following CIS
- For Non-aggressive MS group: no conversion to MS within 2 years or conversion treated or untreated with first line therapy within 2 years
- Minimum of at least 2 years of follow-up for Non-aggressive MS group
- Healthy volunteers aged 18 years or older with no history of CIS or MS
- Pairing criteria: age within +/- 5 years and sex
- Prospective MS patients aged 18 years or older with CIS with or without dissemination in space
- Patients affiliated to an appropriate health insurance
You will not qualify if you...
- Ongoing participation in another study
- Refusal to genetic analyses
- Use of immunosuppressive drugs at the time of blood collection
- Plasma exchange or corticosteroid treatment within four weeks before blood sample
- Adults under legal protection regimes (guardianship, trusteeship, judicial safeguard)
- Pregnancy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Nantes University Hospital
Nantes, Loire-Atlantique, France, 44093
Actively Recruiting
Research Team
D
David LAPLAUD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
BASIC_SCIENCE
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here